A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2026

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

Envafolimab

With or without Envafolimab

Trial Locations (1)

Hebei, Shijiazhuang

All Listed Sponsors

lead

Hebei Medical University Fourth Hospital

OTHER